Illumina (NASDAQ:ILMN) Issues Q4 2025 Earnings Guidance

Illumina (NASDAQ:ILMN) updated its fourth quarter 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 1.270-1.300 for the period. The company issued revenue guidance of $1.2 billion-$1.2 billion. Illumina also updated its FY 2025 guidance to 4.760-4.790 EPS.

Illumina Trading Up 0.5%

ILMN stock traded up $0.71 on Tuesday, reaching $146.26. The company’s stock had a trading volume of 857,805 shares, compared to its average volume of 1,752,380. The firm has a market cap of $22.35 billion, a PE ratio of 32.79, a PEG ratio of 2.35 and a beta of 1.41. The business has a fifty day simple moving average of $130.52 and a two-hundred day simple moving average of $110.24. Illumina has a 12-month low of $68.70 and a 12-month high of $153.06. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the firm earned $1.14 EPS. The company’s quarterly revenue was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, research analysts forecast that Illumina will post 4.51 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on ILMN. JPMorgan Chase & Co. increased their price target on shares of Illumina from $105.00 to $130.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. Wall Street Zen lowered Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, January 3rd. Robert W. Baird set a $109.00 target price on Illumina in a research note on Friday, October 31st. UBS Group upped their price target on Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Finally, Barclays raised their price objective on Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research report on Monday, December 15th. Five equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $122.56.

Insider Buying and Selling

In related news, Director Scott Gottlieb acquired 500 shares of the stock in a transaction on Monday, November 3rd. The stock was acquired at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the purchase, the director owned 12,523 shares of the company’s stock, valued at $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the sale, the insider directly owned 17,887 shares in the company, valued at $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.17% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ILMN. Quarry LP bought a new position in shares of Illumina in the third quarter worth approximately $32,000. Advisory Services Network LLC bought a new stake in shares of Illumina during the third quarter valued at approximately $102,000. Headlands Technologies LLC purchased a new position in Illumina in the 2nd quarter worth approximately $165,000. Glenmede Investment Management LP bought a new position in Illumina in the 3rd quarter valued at approximately $220,000. Finally, Voleon Capital Management LP purchased a new stake in Illumina during the 3rd quarter valued at $220,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.